Percutaneous, oral, or intravesical BCG administration: what is the optimal route?
Lamm
D L
DL
Department of Urology, West Virginia University, Morgantown.
Sarodosy
M S
MS
DeHaven
J I
JI
D000279:Administration, Cutaneous; D000283:Administration, Intravesical; D000284:Administration, Oral; D001500:BCG Vaccine / Q000008:administration & dosage*; D002278:Carcinoma in Situ / Q000628:therapy; D002295:Carcinoma, Transitional Cell / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D009364:Neoplasm Recurrence, Local; D001749:Urinary Bladder Neoplasms / Q000628:therapy*
D001500:BCG Vaccine